Jeffrey A. Meyerhardt, MD, MPH, on Colon Cancer: Results From the ACTS-CC 02 Trial on Adjuvant Chemotherapy
2019 Gastrointestinal Cancers SymposiumJeffrey A. Meyerhardt, MD, MPH, of Dana-Farber Cancer Institute, discusses phase III study findings on S-1/oxaliplatin vs uracil and tegafur/leucovorin as adjuvant chemotherapy for high-risk stage III colon cancer (Abstract 484).
Related Videos
Andrew X. Zhu, MD, PhD, on Liver Cancer: Outcomes in the REFLECT Study on Lenvatinib
Andrew X. Zhu, MD, PhD, of the Massachusetts General Hospital Cancer Center, discusses an analysis of survival and objective response in patients with hepatocellular carcinom...
Francesca Battaglin, MD, on Colorectal Cancer: Using Genetic Variants to Predict Treatment Efficacy
Francesca Battaglin, MD, of the University of Southern California Norris Comprehensive Cancer Center, discusses phase III study data on genetic variants used to predict the e...
Heinz-Josef Lenz, MD, on Pancreatic Cancer Tumor Profiling and Treatment Response: Results From the COMPASS Trial
Heinz-Josef Lenz, MD, discusses molecular profiling and response to chemotherapy in the COMPASS study, which was designed to evaluate the feasibility of using genomic sequenc...
Manish A. Shah, MD, on Gastric Cancer: Results From the GAMMA-1 Study on First-Line Combination Therapy
Manish A. Shah, MD, of NewYork–Presbyterian/Weill Cornell Medical Center, discusses phase III data on the efficacy and safety of andecaliximab combined with mFOLFOX6 as first...
Ahmed Omar Kaseb, MD, on Liver Cancer: Results From an Immunotherapy Trial
Ahmed Omar Kaseb, MD, of The University of Texas MD Anderson Cancer Center, discusses phase II study findings on nivolumab alone vs nivolumab plus ipilimumab in patients with...
